CervoMed Announces Orphan Drug Designation Granted to Neflamapimod by U.S. Food and Drug Administration for the Treatment of Frontotemporal Dementia
CervoMed宣佈, nefamapimod已獲得美國食品藥品監督管理局授予的孤兒藥資格,用於治療額顳葉癡呆。
CervoMed Announces Orphan Drug Designation Granted to Neflamapimod by U.S. Food and Drug Administration for the Treatment of Frontotemporal Dementia
CervoMed宣佈, nefamapimod已獲得美國食品藥品監督管理局授予的孤兒藥資格,用於治療額顳葉癡呆。
譯文內容由第三人軟體翻譯。
使用瀏覽器的分享功能,分享給你的好友吧